Amylyx Pharmaceuticals (AMLX)

• Market cap: $325M
• 1 day: -6.14%
• 5 days: 0.55%
• 1 month: 2.23%
• 3 months: -10.92%
• 6 months: 40.08%
• Year to date: -6.14%
• 1 year: 6.69%
• 5 years: -79.69%
• 10 years: -79.69%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Employees: 123

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 20

34% more capital invested

Capital invested by funds: $141M [Q3] → $189M (+$47.5M) [Q4]

9% more funds holding

Funds holding: 109 [Q3] → 119 (+10) [Q4]

8.83% more ownership

Funds ownership: 63.97% [Q3] → 72.8% (+8.83%) [Q4]

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $1.94M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 227% upside
• Avg. target: $12 227% upside
• High target: $12 227% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 351 met price target

227% upside $12

Buy Reiterated

5 Mar 2025